Signaling Pathways and Emerging Therapies in Multiple Myeloma

Overview

Journal Curr Hematol Malig Rep

Publisher Current Science

Specialties Hematology
Oncology

Date 2016 Feb 29

PMID 26922744

Citations 11

Authors

Vijay Ramakrishnan

Anita DSouza

Affiliations

Soon will be listed here.

Abstract

Multiple myeloma (MM) is a devastating malignancy of antibody-producing plasma cells. In the absence of a single unifying genetic event contributing to disease manifestation, efforts have focused on understanding signaling events deregulated in myeloma plasma cells. MM cells are dependent on both cellular and non-cellular components of the tumor microenvironment such as bone marrow stromal cells, endothelial cells, and cytokines such as interleukin 6 (IL6), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF) for their growth and survival. The cumulative effect of such interactions is the aberrant activation of numerous signal transduction pathways within the MM plasma cells leading to uncontrolled growth and prevention of apoptosis. Here, we will review our current understanding of some of the key signal transduction pathways dysregulated in MM and emerging therapies targeting these pathways in MM.

Citing Articles

Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity.

Lind J, Aksoy O, Prchal-Murphy M, Fan F, Fulciniti M, Stoiber D Blood Cancer J. 2024; 14(1):138.

PMID: 39160158 PMC: 11333473. DOI: 10.1038/s41408-024-01117-4.

Protective Effects of High-Density Lipoprotein on Cancer Risk: Focus on Multiple Myeloma.

Allegra A, Murdaca G, Mirabile G, Gangemi S Biomedicines. 2024; 12(3).

PMID: 38540127 PMC: 10967848. DOI: 10.3390/biomedicines12030514.

Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma.

Iannozzi N, Marchica V, Toscani D, Garcia J, Giuliani N, Storti P Int J Mol Sci. 2022; 23(24).

PMID: 36555090 PMC: 9779562. DOI: 10.3390/ijms232415448.

Expression level of miRNA in the peripheral blood of patients with multiple myeloma and its clinical significance.

Li G, Yin J, Wu Z, Li S, He A, Sun Z Am J Transl Res. 2021; 13(5):5343-5349.

PMID: 34150128 PMC: 8205780.

Suppression of multiple myeloma by mitochondrial targeting.

Aisen Y, Gatt M, Hertz R, Smeir E, Bar-Tana J Sci Rep. 2021; 11(1):5862.

PMID: 33712631 PMC: 7955047. DOI: 10.1038/s41598-021-83829-2.

References

Alsina M, Fonseca R, Wilson E, Belle A, Gerbino E, Price-Troska T . Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004; 103(9):3271-7. DOI: 10.1182/blood-2003-08-2764. View

Annunziata C, Davis R, Demchenko Y, Bellamy W, Gabrea A, Zhan F . Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007; 12(2):115-30. PMC: 2730509. DOI: 10.1016/j.ccr.2007.07.004. View

Kohn A, Takeuchi F, Roth R . Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J Biol Chem. 1996; 271(36):21920-6. DOI: 10.1074/jbc.271.36.21920. View

Le Gouill S, Pellat-Deceunynck C, Harousseau J, Robillard N, Bataille R, Amiot M . Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia. 2002; 16(9):1664-7. DOI: 10.1038/sj.leu.2402629. View

ONeil B, Goff L, Kauh J, Strosberg J, Bekaii-Saab T, Lee R . Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2011; 29(17):2350-6. PMC: 3107750. DOI: 10.1200/JCO.2010.33.9432. View

Yordanova A, Hose D, Neben K, Witzens-Harig M, Gutgemann I, Raab M . Sorafenib in patients with refractory or recurrent multiple myeloma. Hematol Oncol. 2013; 31(4):197-200. DOI: 10.1002/hon.2043. View

Keats J, Reiman T, Maxwell C, Taylor B, Larratt L, Mant M . In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2002; 101(4):1520-9. DOI: 10.1182/blood-2002-06-1675. View

Alessi D, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P . Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996; 15(23):6541-51. PMC: 452479. View

Hayden M, Ghosh S . NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012; 26(3):203-34. PMC: 3278889. DOI: 10.1101/gad.183434.111. View

10.

Ramakrishnan V, Ansell S, Haug J, Grote D, Kimlinger T, Stenson M . MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. Leukemia. 2011; 26(2):340-8. PMC: 4384189. DOI: 10.1038/leu.2011.192. View

11.

Rasmussen T, Kuehl M, Lodahl M, Johnsen H, Dahl I . Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood. 2004; 105(1):317-23. DOI: 10.1182/blood-2004-03-0833. View

12.

Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D . The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther. 2002; 1(7):539-44. View

13.

Cirstea D, Santo L, Hideshima T, Eda H, Mishima Y, Nemani N . Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma. Mol Cancer Ther. 2014; 13(11):2489-500. DOI: 10.1158/1535-7163.MCT-14-0147. View

14.

Zarnegar B, Wang Y, Mahoney D, Dempsey P, Cheung H, He J . Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol. 2008; 9(12):1371-8. PMC: 2676931. DOI: 10.1038/ni.1676. View

15.

Chang H, Qi X, Claudio J, Zhuang L, Patterson B, Stewart A . Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res. 2005; 30(3):262-5. DOI: 10.1016/j.leukres.2005.07.008. View

16.

Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J . Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013; 3(8):862-9. DOI: 10.1158/2159-8290.CD-13-0014. View

17.

McMillin D, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N . Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 2009; 69(14):5835-42. DOI: 10.1158/0008-5472.CAN-08-4285. View

18.

Zollinger A, Stuhmer T, Chatterjee M, Gattenlohner S, Haralambieva E, Muller-Hermelink H . Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood. 2008; 112(8):3403-11. DOI: 10.1182/blood-2007-11-119362. View

19.

Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C . Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006; 107(10):4053-62. PMC: 1895278. DOI: 10.1182/blood-2005-08-3434. View

20.

Chng W, Gonzalez-Paz N, Price-Troska T, Jacobus S, Rajkumar S, Oken M . Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia. 2008; 22(12):2280-4. PMC: 3864109. DOI: 10.1038/leu.2008.142. View